Acotec Scientific Holdings (HKSE:06669) ROCE % : -0.31% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Acotec Scientific Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -0.31%.

Acotec Scientific Holdings ROCE % Historical Data

The historical data trend for Acotec Scientific Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings ROCE % Chart

Acotec Scientific Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

51.25

-11.61

5.42

1.71

Acotec Scientific Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial				-20.03	5.04	6.09	3.72	-0.31

Acotec Scientific Holdings ROCE % Calculation

Acotec Scientific Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	26.562	/	( ( (1575.176 - 110.192)	+	(1762.14 - 127.146) )	/ 2 )
	=	26.562	/	( (1464.984	+	1634.994)	/ 2 )
	=	26.562	/	1549.989
	=	1.71 %

Acotec Scientific Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-5.028	/	( ( (1754.996 - 96.352)	+	(1762.14 - 127.146) )	/ 2 )
	=	-5.028	/	( ( 1658.644	+	1634.994 )	/ 2 )
	=	-5.028	/	1646.819
	=	-0.31 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Acotec Scientific Holdings (HKSE:06669) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Acotec Scientific Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acotec Scientific Holdings (HKSE:06669) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

7W3:Germany

Address

16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN

Website

http://www.acotec.cn

Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.

Executives

Vistra Trust (singapore) Pte. Limited	2301 Trustee
Nexus Partners Group Limited	2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited	2101 Beneficial owner
Li Jing	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p.	2201 Interest of corporation controlled by you
Cpe Funds Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited	2101 Beneficial owner
Cpe Holdings Limited	2201 Interest of corporation controlled by you
Cpe Holdings International Limited	2201 Interest of corporation controlled by you
Cpe Gof Gp Limited	2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p.	2201 Interest of corporation controlled by you
Boston Scientific Corporation	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings (HKSE:06669) Headlines

No Headlines